Research & Literature

Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison.

Vanhoutte EK, Draak TH, Gorson KC, et al.

Journal of the peripheral nervous system : JPNS 2015; (20(3)):289-95 doi:10.1111/jns.12118.

Thrombocytosis distinguishes POEMS syndrome from chronic inflammatory demyelinating polyneuropathy.

Naddaf E, Dispenzieri A, Mandrekar J, Mauermann ML

Muscle & nerve 2015; (52(4)):658-9 doi:10.1002/mus.24768.

Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.

Adrichem ME, Eftimov F, van Schaik IN

Journal of the peripheral nervous system : JPNS 2016; (21(3)):121-7 doi:10.1111/jns.12176.

Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.

Markvardsen LH, Sindrup SH, Christiansen I, et al.

European journal of neurology 2017; (24(2)):412-418 doi:10.1111/ene.13218.

Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.

Oaklander AL, Lunn MP, Hughes RA, et al.

The Cochrane database of systematic reviews 2017; (1()):CD010369 doi:10.1002/14651858.CD010369.pub2.

Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground.

Uncini A, Vallat JM

Journal of neurology, neurosurgery, and psychiatry 2018; (89(6)):627-635 doi:10.1136/jnnp-2017-317192.

IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG.

Berger M, Harbo T, Cornblath DR, Mielke O

Immunotherapy 2018; (10(11)):919-933 doi:10.2217/imt-2018-0036.

[The clinical analysis of diabetic patients with chronic inflammatory demyelinating polyradiculoneuropathy].

Sun QL, Sun AP, Fu Y, Fan DS

Zhonghua nei ke za zhi 2018; (57(10)):749-752 doi:10.3760/cma.j.issn.0578-1426.2018.10.010.

Diagnostic usefulness of plexus magnetic resonance imaging in chronic inflammatory demyelinating polyradiculopathy without electrodiagnostic criteria of demyelination.

Fargeot G, Viala K, Theaudin M, et al.

European journal of neurology 2019; (26(4)):631-638 doi:10.1111/ene.13868.

POEMS syndrome: clinical update.

Brown R, Ginsberg L

Journal of neurology 2019; (266(1)):268-277 doi:10.1007/s00415-018-9110-6.

Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis.

Broers MC, Bunschoten C, Nieboer D, et al.

Neuroepidemiology 2019; (52(3-4)):161-172 doi:10.1159/000494291.

Chronic immune sensorimotor polyradiculopathy: Report of a case series.

Thammongkolchai T, Suhaib O, Termsarasab P, et al.

Muscle & nerve 2019; (59(6)):658-664 doi:10.1002/mus.26436.

Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo.

Manso C, Querol L, Lleixà C, et al.

The Journal of clinical investigation 2019; (129(6)):2222-2236.

Subcutaneous immunoglobulin treatment and leucopenia in acquired demyelinating peripheral neuropathies.

Vacchiano V, Liguori R, Avoni P, et al.

European journal of neurology 2019; (26(9)):e80-e81 doi:10.1111/ene.13933.

Defining chronic inflammatory demyelinating polyradiculoneuropathy subtypes.

Hughes RAC

Journal of neurology, neurosurgery, and psychiatry 2019; (90(9)):963 doi:10.1136/jnnp-2019-321250.

Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy.

Ikeda S, Koike H, Nishi R, et al.

Journal of neurology, neurosurgery, and psychiatry 2019; (90(9)):988-996 doi:10.1136/jnnp-2019-320741.

Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.

Hartung HP, Mallick R, Bril V, et al.

European journal of neurology 2020; (27(1)):196-203 doi:10.1111/ene.14056.

Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy.

Bunschoten C, Blomkwist-Markens PH, Horemans A, et al.

Journal of the peripheral nervous system : JPNS 2019; (24(3)):253-259 doi:10.1111/jns.12344.

Chronic Inflammatory Demyelinating Polyneuropathy.

Kuwabara S, Misawa S

Advances in experimental medicine and biology 2019; (1190()):333-343 doi:10.1007/978-981-32-9636-7_21.

Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features.

Tang L, Huang Q, Qin Z, Tang X

Journal of neurology 2021; (268(8)):2757-2768 doi:10.1007/s00415-020-09823-2.

RELEVANCE OF DIAGNOSTIC INVESTIGATIONS IN CHRONIC INFLAMMATORY DEMYELINATING POLIRADICULONEUROPATHY: DATA FROM THE ITALIAN CIDP DATABASE.

Liberatore G, Manganelli F, Cocito D, et al.

Journal of the peripheral nervous system : JPNS 2020; doi:10.1111/jns.12378.

Antibodies to nodal/paranodal proteins in paediatric immune-mediated neuropathy.

De Simoni D, Ricken G, Winklehner M, et al.

Neurology(R) neuroimmunology & neuroinflammation 2020; (7(4)) doi:10.1212/NXI.0000000000000763.

Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP).

Querol L, Crabtree M, Herepath M, et al.

Journal of neurology 2021; (268(10)):3706-3716 doi:10.1007/s00415-020-09998-8.

Chronic immune sensory polyradiculopathy (CISP): First juvenile case description.

Sotgiu S, Minutolo A, Carta A, et al.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(1)):333-336 doi:10.1007/s10072-020-04588-y.

Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera.

Delmont E, Brodovitch A, Kouton L, et al.

Journal of neurology 2020; (267(12)):3664-3672 doi:10.1007/s00415-020-10041-z.

MRI quantifies lumbosacral nerve root and sciatic nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy.

Shah S, Morrow JM, Sinclair CDJ, et al.

European journal of radiology 2020; (130()):109164 doi:10.1016/j.ejrad.2020.109164.

Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy.

Eftimov F, Lucke IM, Querol LA, et al.

Brain : a journal of neurology 2020; (143(11)):3214-3224 doi:10.1093/brain/awaa265.

Increased muscle echointensity correlates with clinical disability and muscle strength in chronic inflammatory demyelinating polyneuropathy.

Fisse AL, Fiegert S, Stoykova Z, et al.

European journal of neurology 2021; (28(5)):1698-1705 doi:10.1111/ene.14716.

Treatment Approaches for Atypical CIDP.

Menon D, Katzberg HD, Bril V

Frontiers in neurology 2021; (12()):653734 doi:10.3389/fneur.2021.653734.

Macrophages and Autoantibodies in Demyelinating Diseases.

Koike H, Katsuno M

Cells 2021; (10(4)) doi:10.3390/cells10040844.

European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.

Journal of the peripheral nervous system : JPNS 2021; (26(3)):242-268 doi:10.1111/jns.12455.

Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis.

Hu J, Sun C, Lu J, et al.

Journal of neurology 2022; (269(3)):1250-1263 doi:10.1007/s00415-021-10646-y.

Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.

Bus SRM, Broers MC, Lucke IM, et al.

Journal of neurology 2022; (269(2)):945-955 doi:10.1007/s00415-021-10677-5.

European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.

Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.

European journal of neurology 2021; (28(11)):3556-3583 doi:10.1111/ene.14959.

Paraproteinemia and neuropathy.

Koike H, Katsuno M

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(11)):4489-4501 doi:10.1007/s10072-021-05583-7.

Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies.

Dalakas MC

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022; (19(3)):741-752 doi:10.1007/s13311-022-01210-1.

Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis.

Auer M, Hegen H, Hotter A, et al.

Journal of central nervous system disease 2022; (14()):11795735221084837 doi:10.1177/11795735221084837.

Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands.

Broers MC, de Wilde M, Lingsma HF, et al.

Journal of the peripheral nervous system : JPNS 2022; (27(3)):182-188 doi:10.1111/jns.12502.

Tips in navigating the diagnostic complexities of chronic inflammatory demyelinating polyradiculoneuropathy.

Lewis RA, van Doorn PA, Sommer C

Journal of the neurological sciences 2022; (443()):120478 doi:10.1016/j.jns.2022.120478.

Chronic inflammatory demyelinating polyradiculoneuropathy: Diagnostic problems in clinical practice in Serbia.

Basta I, Delic N, Gunjic I, et al.

Journal of the peripheral nervous system : JPNS 2023; (28(2)):226-236 doi:10.1111/jns.12537.

Growing Spectrum of Autoimmune Nodopathies.

Gupta P, Mirman I, Shahar S, Dubey D

Current neurology and neuroscience reports 2023; (23(5)):201-212 doi:10.1007/s11910-023-01264-4.

Current clinical management of CIDP with immunoglobulins in France: An expert opinion.

Cintas P, Bouhour F, Cauquil C, et al.

Revue neurologique 2023; (179(8)):914-922 doi:10.1016/j.neurol.2023.03.010.

Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: Potential relevance of antibody titers in monitoring treatment response.

Bresciani L, Salvalaggio A, Vegezzi E, et al.

Journal of the peripheral nervous system : JPNS 2023; (28(3)):522-527 doi:10.1111/jns.12565.

Autoimmune nodo-paranodopathies 10 years later: Clinical features, pathophysiology and treatment.

Uncini A

Journal of the peripheral nervous system : JPNS 2023; (28 Suppl 3()):S23-S35 doi:10.1111/jns.12569.

Molecular, Electrophysiological, and Ultrasonographic Differences in Selected Immune-Mediated Neuropathies with Therapeutic Implications.

Dziadkowiak E, Nowakowska-Kotas M, Rałowska-Gmoch W, et al.

International journal of molecular sciences 2023; (24(11)) doi:10.3390/ijms24119180.

How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast.

Desai U

Neurology and therapy 2023; (12(5)):1409-1417 doi:10.1007/s40120-023-00512-6.

Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants.

De Lorenzo A, Liberatore G, Doneddu PE, et al.

European journal of neurology 2024; (31(4)):e16190 doi:10.1111/ene.16190.

Clinical Features of Autoimmune Nodopathy With Anti-Neurofascin-155 Antibodies in South Koreans.

Lyou HJ, Chung YH, Kim MJ, et al.

Journal of clinical neurology (Seoul, Korea) 2024; (20(2)):186-193 doi:10.3988/jcn.2023.0055.

Peripheral Nervous System (PNS) Myelin Diseases.

Scherer SS, Svaren J

Cold Spring Harbor perspectives in biology 2024; (16(5)) doi:10.1101/cshperspect.a041376.

Challenges in the Early Diagnosis and Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Adults: Current Perspectives.

van Doorn IN, Eftimov F, Wieske L, et al.

Therapeutics and clinical risk management 2024; (20()):111-126 doi:10.2147/TCRM.S360249.

[Cutting edge of diagnosis and treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) based on the EAN/PNS guideline 2021].

Kuwabara S

Rinsho shinkeigaku = Clinical neurology 2024; (64(5)):321-325 doi:10.5692/clinicalneurol.cn-001937.

Clinical characteristics of patients with autoimmune nodopathy with anti-neurofascin155 antibodies.

Zhang J, Hou X, Wei L, et al.

Frontiers in immunology 2024; (15()):1345953 doi:10.3389/fimmu.2024.1345953.

Subcutaneous immunoglobulins (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIDP): A comprehensive systematic review of clinical studies and meta-analysis.

Ramzi A, Maya S, Balousha N, et al.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2024; (45(11)):5213-5230 doi:10.1007/s10072-024-07640-3.

Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort.

Quint P, Schroeter CB, Kohle F, et al.

Journal of neurology 2024; (271(9)):5930-5943 doi:10.1007/s00415-024-12548-1.

[Clinical features of anti-neurofascin-155 antibody positive autoimmune nodopathy in 6 children].

Fang ZX, Zhang M, Hu CP, et al.

Zhonghua er ke za zhi = Chinese journal of pediatrics 2024; (62(8)):780-785 doi:10.3760/cma.j.cn112140-20240228-00130.

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.

Allen JA, Lin J, Basta I, et al.

The Lancet. Neurology 2024; (23(10)):1013-1024 doi:10.1016/S1474-4422(24)00309-0.

[Pathomechanism Underlying Intravenous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy].

Shimizu F

Brain and nerve = Shinkei kenkyu no shinpo 2024; (76(10)):1109-1118 doi:10.11477/mf.1416202746.

Validation of the Korean version of inflammatory Rasch-built Overall Disability Scale in patients with inflammatory neuropathy.

Ju W, Min YG, Kim JS, et al.

Journal of the peripheral nervous system : JPNS 2025; (30(1)):e12676 doi:10.1111/jns.12676.

Distinguishing Chronic Inflammatory Demyelinating Polyneuropathy From Mimic Disorders: The Role of Statistical Modeling.

Swart G, Skolka MP, Shelly S, et al.

Journal of the peripheral nervous system : JPNS 2025; (30(1)):e12682 doi:10.1111/jns.12682.

Clinical Manifestations and Treatment Responses in Pediatric Neurofascin 155-IgG4 Autoimmune Nodopathy.

Rashed HR, Paramasivan NK, Selcen D, et al.

Neurology(R) neuroimmunology & neuroinflammation 2025; (12(2)):e200368 doi:10.1212/NXI.0000000000200368.

Evaluating Grasp Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Using Dynamometers: A Comprehensive Review.

Tsoumanis P, Chatzoglou T, Smyris TI, et al.

Journal of clinical medicine research 2025; (17(3)):136-144 doi:10.14740/jocmr6179.

Short-term treatment of CIDP with efgartigimod: a case series in China.

Sun C, Hu J, Zhao Y, et al.

Frontiers in immunology 2025; (16()):1533167 doi:10.3389/fimmu.2025.1533167.

Role of Imaging in Chronic Inflammatory Demyelinating Polyneuropathy: A Systematic Review.

Tozza S, Cassano E, Erra C, et al.

European journal of neurology 2025; (32(6)):e70226 doi:10.1111/ene.70226.

POEMS syndrome presenting with Vibrio vulnificus-like cutaneous lesions: a CARE guidelines-compliant case report.

Li X, Lin B, Lin L, Song C

Frontiers in medicine 2025; (12()):1625877 doi:10.3389/fmed.2025.1625877.

Outcome measures in CIDP: A scoping and mapping review.

Rajabally YA, Boggia GM, Riley D, et al.

Journal of the neurological sciences 2025; (477()):123654 doi:10.1016/j.jns.2025.123654.

Minimal Clinically Important Difference for the Jamar Hand Grip Dynamometer in CIDP: A Korea-UK Study.

Min YG, Rajabally Z, Ju W, et al.

European journal of neurology 2025; (32(8)):e70335 doi:10.1111/ene.70335.

Clinical characteristics of anti-neurofascin 155 antibody-positive autoimmune nodopathy in children.

Cui L, Gong S, Zhao Y, et al.

Pediatric investigation 2025; (9(3)):275-281 doi:10.1002/ped4.70008.

Complement profiling of sural nerves in chronic-inflammatory demyelinating polyneuropathy.

Stascheit F, Roos A, Schroeter CB, et al.

Acta neuropathologica 2025; (150(1)):32 doi:10.1007/s00401-025-02936-w.

POEMS Syndrome Without a Detectable Monoclonal Peak: The Critical Role of VEGF and Bone Marrow Biopsy in Diagnosis.

J Pecorin P, A MM, Olson G, et al.

Case reports in hematology 2025; (2025()):5530850 doi:10.1155/crh/5530850.

Atypical diabetic neuropathies.

McCray BA, Stino AM, Davalos L, et al.

BMJ (Clinical research ed.) 2025; (390()):e081109 doi:10.1136/bmj-2024-081109.

Comparison of the presentation and electrophysiological characteristics of autoimmune nodopathies in patients with antibody-negative CIDP and CMT1.

Song C, Liu H

Frontiers in neurology 2025; (16()):1617545 doi:10.3389/fneur.2025.1617545.

The potential role of IgG subclass in NF155-associated nodopathy for targeting therapy: a pediatric case report highlighting the efficacy of pulsed oral corticosteroids.

Turčanová Koprušáková M, Kurča E, Trusiková E, et al.

BMC neurology 2025; (25(1)):451 doi:10.1186/s12883-025-04467-z.

Autoimmune Nodopathy With Anti-Neurofascin 186 Antibody.

Anilkumar A, Krishnan P

Cureus 2025; (17(11)):e96112 doi:10.7759/cureus.96112.

Efficacy of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy with or without diabetes: insights from a multicenter prospective comparative study.

Macwan SP, Mahajan S, Novak P, et al.

Therapeutic advances in neurological disorders 2025; (18()):17562864251401496 doi:10.1177/17562864251401496.

Practical Approach to Managing SCIg Treatment in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.

Vu T, Guerra C, Suresh N, et al.

Muscle & nerve 2026; (73(5)):765-771 doi:10.1002/mus.70151.

Advances in the treatment of autoimmune nodopathy: based on treatment strategies of CIDP.

Pang ZD, Sun H, Wei XJ, et al.

Frontiers in immunology 2026; (17()):1735745 doi:10.3389/fimmu.2026.1735745.